KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Sales and Divestitures (2016 - 2025)

Sarepta Therapeutics (SRPT) has 14 years of Gains from Sales and Divestitures data on record, last reported at $38050.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 60.96% year-over-year to $38050.0; the TTM value through Sep 2025 reached $38050.0, down 60.96%, while the annual FY2024 figure was $44300.0, 93.13% down from the prior year.
  • Gains from Sales and Divestitures reached $38050.0 in Q3 2025 per SRPT's latest filing, roughly flat from $38050.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $644614.0 in Q4 2023 and bottomed at $38050.0 in Q2 2025.
  • Average Gains from Sales and Divestitures over 5 years is $193376.1, with a median of $48875.0 recorded in 2021.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 697.46% in 2022, then crashed 93.13% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $48875.0 in 2021, then soared by 697.46% to $389761.0 in 2022, then surged by 65.39% to $644614.0 in 2023, then plummeted by 93.13% to $44300.0 in 2024, then decreased by 14.11% to $38050.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $38050.0 in Q3 2025, $38050.0 in Q2 2025, and $44300.0 in Q4 2024.